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between 1960 and 2015 in English language. Phase II, III or IV clinical trials with at-
least one study arm assessing a treatment of interest were included. PRO studies 
(not limited to RCTs) reporting quality-of-life (QoL) data for these compounds were 
included. Additionally, information was extracted from product package inserts 
of molecules within FDA indication. Archives of 27 HTA bodies were searched for 
qualifying HTAs of these compounds as well. Patient characteristics, primary and 
secondary endpoints, safety, QoL and reimbursement decisions were extracted 
exhaustively from qualifying studies and HTAs. Results: So far, data are avail-
able for 15 cancers, including 90 agents in 487 studies. The interactive, user-friendly 
MS-Excel® based tool can be used to study any selected cancer, including conduct 
meta-analyses, generate summaries and reports of clinical, PRO and HTA data. The 
registry provides functionality for a user to make desired assessments via multiple 
variables such as line of treatment, tumor-stage, molecule, grade of adverse events 
and so on. ConClusions: OncoLitBank provides up-to-date data and a robust 
platform that can be easily used for systematic reviews, to conduct direct and indi-
rect comparisons through meta-analyses, to inform economic models, perform 
landscape analyses, produce value dossiers,and to create target product profiles and 
value development plans. Expansion of searches to other literature databases and 
trial registries and inclusion of economic and epidemiology studies are underway.
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objeCtives: To generate costs and costing algorithms for treatment and supportive 
drugs in oncology using provincial (Ontario) administrative databases. Methods: 
A cohort of women diagnosed with breast cancer (BC) (ICD-9 174.x) was identi-
fied from the Ontario Cancer Registry (2007-2010). Firstly, the Ontario Drug Benefit 
Formulary (ODBF), New Drug Funding Program (NDFP) and Activity Level Reporting 
(ALR) databases was used in which BC-specific treatments (chemotherapies and 
hormonal therapies) and supportive drugs were identified. Secondly, unit costs were 
applied to calculate the overall and per drug costs in each database. Lastly, costing 
algorithms were generated to conduct the costing analyses. Results: We identified 
30,338 women diagnosed with BC. All chemotherapies and hormonal therapies were 
named as well as anti-nausea, pain (opioid and non-opioid), anti-infectives, and 
blood products for supportive drugs. Outputs include number of patient cases with 
at least one treatment or supportive drug being utilized and total costs. Preliminary 
results for the 20,076 BC cases prescribed a drug in ODBF totalled $69.5 million in 
which $37.5 million was treatment-specific. ConClusions: We have generated 
preliminary ODBF costs for oncology drugs in BC and costs for the NDFP and ALR 
databases will be determined next. These costing algorithms will allow for the calcu-
lation of oncology treatment and supportive drug costs in different cancer cohorts.
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objeCtives: Repositories of “big data” have the potential to play a pivotal role in 
advancing Alzheimer’s disease (AD) research. Globally, AD-specific data are being 
generated and aggregated into research databases. An environmental scan was 
conducted to identify worldwide AD-specific databases and types of data being 
aggregated and used for AD research. Methods: A Google search was conducted 
monthly starting in September 2014 to present. For each database, its URL, geo-
graphic location, funding source, and type of data collected and/or stored were 
identified. A categorization scheme was established to classify types of data. Three 
reviewers independently categorized the data as: 1 = claims, 2 = laboratory, 3 = 
genetic, 4 = imaging, 5 = patient/caregiver-reported questionnaires, 6a= longitudi-
nal study, 6b = patient registry, 7 = clinical data, 8 = electronic medical records, 9 = 
neuropathology, and O = other. A fourth reviewer resolved discrepancies. Results: 
A total of 53 AD databases were identified, both within (28/53) and outside the U.S. 
(21/53). Sources from outside the U.S. include United Kingdom, Australia, Belgium, 
France, etc. Four databases represent U.S. and non-U.S. collaborations. The National 
Institutes of Health is the most common funding source (14/53). Clinical data were 
found to be the most common (30/53); whereas, databases containing AD-specific 
claims data appear to be lacking. Additional gaps include a comprehensive database 
linking claims data with patient-level data from AD longitudinal studies, patient 
registries, electronic medical records, or genetic data. Patient registry databases 
lack pre-diagnosis and early-life data, as they enroll patients upon diagnosis with 
AD or mild cognitive impairment. ConClusions: Various types of data are being 
aggregated into numerous AD-specific research databases worldwide. However, gaps 
exist that may limit the utility of these databases in making advances in the AD 
research. Efforts are needed to explore opportunities to merge and expand these 
databases to fill these critical gaps.
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objeCtives: Social Listening through digital media may offer a unique opportunity 
to enhance traditional pharmacovigilance strategies. The objective of this pilot study 
was to evaluate the breadth of pharmaceutical products and vaccines most com-
monly discussed on Facebook and Twitter and how these data may inform future 
research in this area. Methods: Publically available Facebook and Twitter posts 
of lifetime direct medical costs for first-ever stroke patients can have implication 
in public health policy planning and clinical decision making.
ReseaRCh on MethoDs – Databases & Management Methods
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objeCtives: Several indices have been developed to adjust for the effects of comor-
bid conditions in observational studies. This study aimed to determine which among 
selected indices provides the optimal covariate in cost analyses assessing resource 
utilisation between different treatment strategies using a UK primary care data-
base. Methods: A retrospective analysis of UK patients continuously registered 
with a single general medical practice between 01/01/2007 and 01/01/2011 was con-
ducted using the Clinical Practice Research Datalink GOLD dataset (CPRD). Three 
comorbidity indices were compared: the Charlson Comorbidity Index, original ver-
sion (CCI) and 2008 adaptation (CCI-2008), and the Quality Outcomes Framework 
(QOF). In addition, we considered a bespoke index based on an unweighted count 
of diseases included in the Charlson indices. Two resource use outcomes were 
analysed: 1) the monthly frequency of primary care consultations; and 2) annual 
count of biological tests reported over the calendar year 2010. The sensitivity of 
the comorbidity indices were evaluated for three different look-back periods: 12, 
24 and 36 months. For each outcome, we fitted mixed linear regression models 
with comorbidity index, age and gender as fixed-effects factors and covariates, and 
general practice as random intercept. Comorbidity indices were ranked according to 
goodness-of-fit, assessed by R2 and Akaike’s Information Criterion (AIC). Results: 
4,694,610 patients were included in the analysis. The CCI-2008 ranked highest based 
on correlation with both consultations (R2= 0.11) and tests (R2= 0.16), followed by the 
CCI (R2= 0.09 and R2= 0.14 for consultations and tests respectively) and then the QOF 
measure (R2= 0.08 and R2= 0.11 respectively). Unweighted counts of comorbidities 
showed similar AIC and R2 as their weighted counterparts. The same ranking was 
observed over the three co-morbidity look-back periods. ConClusions: The CCI-
2008 performed better than CCI and QOF to predict units of primary care resource 
utilisation observed in UK general practice. Further analyses will determine whether 
these findings are confirmed when predicting health resource use costs and if repro-
ducible in other health systems with alternative data collection methods such as 
claims databases.
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objeCtives: Multiple sclerosis (MS) is a degenerative neurologic disease that seri-
ously affects patients’ quality of life. Fingolimod is a sphingosine-1-phosphate 
modulator that traps lymphocytes in lymph nodes with neuroprotective effects. 
Our objective was to review the available evidence regarding its efficacy in disease 
progressions, relapse rate and brain atrophy and link it to possible phamaeconomic 
effects. Methods: A systematic review of literature was performed in MEDLINE 
and Scopus. We included primary studies comparing fingolimod to placebo or other 
drugs regarding its efficacy in disease progression, relapse rate and brain atrophy. 
Retrospective designs and studies focusing on specific populations were excluded. 
Data regarding the outcomes of interest were extracted and processed with Review 
Manager 5.3. Results were presented with forest plots, and heterogeneity analysis 
was performed. We performed a literature review to assess the possible effect of 
these clinical outcomes in terms of costs and quality adjusted life years (QALY) in 
the Colombian context. Results: From the 1,344 references originally identified, 
only 3 had useful information. Two were placebo-controlled and the other one used 
interferon ß1a (IFß1a) as control. Information was available for 1.25 mg and 0.5 mg 
fingolimod dosing. Statistically significant differences in favor of fingolimod were 
found in annualized relapse rate, brain volume change, percentage of relapse and 
disease progression-free patients compared to placebo or IFß1a. Results EDSS and 
MSFC scales change were favorable to fingolimod but not statistically significant. 
Using data from various sources, we estimated that Colombian patients treated 
with fingolimod for 5 years might avoid a loss of 0.145 QALY and $ 5,029 of direct 
and indirect costs. ConClusions: Fingolimod is superior to placebo and IFß1a in 
disease progression, relapse rate and brain atrophy. More studies are warranted, 
especially comparing fingolimod to other drugs. The estimated pharmacoeconomic 
effects are promising but must be interpreted with caution.
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objeCtives: We created OncoLitBank, to capture data from clinical trials, patient 
reported outcomes (PRO) studies,and Health Technology Assessments (HTAs) in 
oncology. The registry is aimed to provide efficient access, and comprehensive anal-
yses of data for the evolving landscape of chemotherapy agents. Methods: A sys-
tematic literature search was conducted on PubMed for chemotherapy compounds 
by cancer indications that were either FDA-approved or National Comprehensive 
Cancer Network (NCCN) recommended. The search was limited to studies published 
